Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
5(21%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
4
17%
Ph phase_1
2
8%
Ph phase_3
1
4%
Ph phase_2
4
17%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
1(9.1%)
N/ANon-phased studies
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

24

all time

Status Distribution
Active(6)
Completed(9)
Other(9)

Detailed Status

Completed9
unknown9
Recruiting4
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 24 (36.4%)
Phase 31 (9.1%)
N/A4 (36.4%)

Trials by Status

completed938%
active_not_recruiting14%
recruiting417%
not_yet_recruiting14%
unknown938%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT05753306Phase 2

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Recruiting
NCT05038098Phase 1

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer

Not Yet Recruiting
NCT05180864Not Applicable

Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer

Recruiting
NCT02205047Phase 2

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

Completed
NCT06798376

Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

Recruiting
NCT02931890Phase 2

Multicentric Randomised Trial for Resectable Gastric Cancer

Active Not Recruiting
NCT05800236Not Applicable

Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine

Unknown
NCT05604378

Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis

Completed
NCT03001726

To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

Unknown
NCT05075421

Prognostic Values of Inflammation-based Indices in Gastric Cancer

Completed
NCT04782791Phase 2

Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer

Unknown
NCT05071755

Gastrectomy Outcomes in Elderly Patients

Unknown
NCT04483076Phase 3

Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer

Recruiting
NCT04481828

Comparison With Open and Totally Laparoscopic Gastrectomy for Gastric Cancer

Completed
NCT03071237

The Origin of Infrapyloric Artery

Completed
NCT01919242

Postoperative Morbidity and Mortality After Gastrectomy for Gastric Cancer: Prospective Cohort Study

Unknown
NCT03251430

Bone Microstructure by Using HR-pQCT in Long Courses After Gastrectomy

Unknown
NCT02313688Not Applicable

Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors

Unknown
NCT02801955

Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma

Completed
NCT01643811

Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
24